Natalizumab
- 1 April 2005
- journal article
- review article
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 40 (4), 336-346
- https://doi.org/10.1177/001857870504000409
Abstract
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2005 omega-3-acid ethyl esters capsules, iloprost inhalation solution, clofarabine, pegaptanib, and meningococcal conjugate vaccine. The DUE is on omega-3-acid ethyl esters capsules.Keywords
This publication has 14 references indexed in Scilit:
- Randomized multicenter trial of natalizumab in acute MS relapsesNeurology, 2004
- Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosisZeitschrift für Neurologie, 2004
- Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrinThe American Journal of Gastroenterology, 2003
- Natalizumab for Active Crohn's DiseaseNew England Journal of Medicine, 2003
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- α4Integrins as Therapeutic Targets in Autoimmune DiseaseNew England Journal of Medicine, 2003
- A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha‐4 integrinAlimentary Pharmacology & Therapeutics, 2002
- A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's diseaseGastroenterology, 2001
- Glioblastoma causing granulocytosis by secretion of granulocyte-colony-stimulating factorNeurology, 2000
- A safety and pharmacokinetic study of intravenous natalizumab in patients with MSNeurology, 1999